{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:24:08Z","timestamp":1790735048150,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T00:00:00Z","timestamp":1357776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Grayson Jockey Club"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["NIH T35RR007061"],"award-info":[{"award-number":["NIH T35RR007061"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Center for Veterinary Health Sciences Short-Term Training Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:p>Equine herpes myeloencephalopathy, resulting from equine herpes virus type 1 (<jats:styled-content style=\"fixed-case\">EHV<\/jats:styled-content>\u20101) infection, is associated with substantial morbidity and mortality in the horse. As compared to other antiviral drugs, such as acyclovir, ganciclovir has enhanced potency against<jats:styled-content style=\"fixed-case\">EHV<\/jats:styled-content>\u20101. This study investigated the pharmacokinetics of ganciclovir and its oral prodrug, valganciclovir, in six adult horses in a randomized cross\u2010over design. Ganciclovir sodium was administered intravenously as a slow bolus at a dose of 2.5\u00a0mg\/kg, and valganciclovir was administered orally at a dose of 1800\u00a0mg per horse. Intravenously administered ganciclovir disposition was best described by a three\u2010compartment model with a prolonged terminal half\u2010life of 72\u00a0\u00b1\u00a09\u00a0h. Following the oral administration of valganciclovir, the mean observed maximum serum ganciclovir concentration was 0.58\u00a0\u00b1\u00a00.37\u00a0\u03bcg\/mL, and bioavailability of ganciclovir from oral valganciclovir was 41\u00a0\u00b1\u00a020%. Superposition predicted that oral dosing of 1800\u2010mg valganciclovir two times daily would fail to produce and maintain effective plasma concentrations of ganciclovir. However, superposition suggested that i.v. administration of ganciclovir at 2.5\u00a0mg\/kg every 8\u00a0h for 24\u00a0h followed by maintenance dosing of 2.5\u00a0mg\/kg every 12\u00a0h would maintain effective ganciclovir serum concentrations in most horses throughout the dosing interval.<\/jats:p>","DOI":"10.1111\/jvp.12029","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T10:25:28Z","timestamp":1357813528000},"page":"441-449","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacokinetics of ganciclovir and valganciclovir in the adult horse"],"prefix":"10.1111","volume":"36","author":[{"given":"R. J.","family":"Carmichael","sequence":"first","affiliation":[{"name":"Department of Veterinary Clinical Sciences Center for Veterinary Health Sciences Oklahoma State University Stillwater OK USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Whitfield","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences Center for Veterinary Health Sciences Oklahoma State University Stillwater OK USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. K.","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Department of Physiological Sciences Center for Veterinary Health Sciences Oklahoma State University Stillwater OK USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100150"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2006.tb02901.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(99)00161-2"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01314149"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.177"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00116-07"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2007.01.004"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2008.01025.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2008.09.062"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030160"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015920023272"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/ajhp\/60.7.687","article-title":"Stability of valganciclovir in extemporaneously compounded liquid formulations","volume":"60","author":"Henkin C.C.","year":"2003","journal-title":"American Journal of Health\u2010System Pharmacy"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090424"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.8.1251"},{"key":"e_1_2_6_16_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0022-3565(25)32415-8","article-title":"Pharmacokinetics and bioavailability of acyclovir in the dog","volume":"216","author":"Krasny H.C.","year":"1981","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2006.01.005"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2009.0304.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2460\/ajvr.1998.59.12.1589","article-title":"Population pharmacokinetics of gentamicin in horses","volume":"59","author":"Martin\u2010Jimenez T.","year":"1998","journal-title":"American Journal of Veterinary Research"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2008.00957.x"},{"key":"e_1_2_6_21_1","first-page":"198","volume-title":"Proceedings of the 54th Annual Convention of the American Association of Equine Practitioners, San Diego, California, USA, 6\u201010 December 2008","author":"Maxwell L.K.","year":"2008"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.650"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.8.4047-4060.2006"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2009.06.033"},{"issue":"1","key":"e_1_2_6_25_1","first-page":"31","article-title":"Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients","volume":"1","author":"Pescovitz M.D.","year":"1999","journal-title":"Transplant Infectious Disease"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2011.01336.x"},{"key":"e_1_2_6_27_1","first-page":"504","article-title":"Isolation and identification of equine rhinopneumonitis virus (equine abortion virus) from cases of abortion and paralysis","volume":"18","author":"Saxegaard F.","year":"1966","journal-title":"Nordisk Veterinaermedicin"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050916"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/10.Supplement_3.S507"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/03639040500271951"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0031-6997(25)06633-5","article-title":"Linearity and superposition in pharmacokinetics","volume":"26","author":"Thron C.D.","year":"1974","journal-title":"Pharmacological Reviews"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.150-157.2001"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.09-0350"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1021016218536"},{"key":"e_1_2_6_35_1","first-page":"394","volume-title":"Acyclovir as Treatment for EHV\u20101 Myeloencephalopathy","author":"Wilkins P.A.","year":"2003"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-4431.2005.00145.x"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.70.12.1545"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544050-00003"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.12.038"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200948050-00004"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvp.12029","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvp.12029","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.12029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T16:45:59Z","timestamp":1745945159000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvp.12029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,10]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/jvp.12029"],"URL":"https:\/\/doi.org\/10.1111\/jvp.12029","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,10]]}}}